Cargando…

Assays and technologies for developing proteolysis targeting chimera degraders

Targeted protein degradation by small-molecule degraders represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase and a protein of interest (POI) into proximity, leading to induced ubiquitination and degradati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xingui, Zhang, Xuan, Lv, Dongwen, Yuan, Yaxia, Zheng, Guangrong, Zhou, Daohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Newlands Press Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333641/ https://www.ncbi.nlm.nih.gov/pubmed/32431173 http://dx.doi.org/10.4155/fmc-2020-0073

Ejemplares similares

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

Proteolysis-targeting chimera against BCL-X(L) destroys tumor-infiltrating regulatory T cells
por: Kolb, Ryan, et al.
Publicado: (2021)

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
por: Lebraud, Honorine, et al.
Publicado: (2016)

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
por: Yamanaka, Satoshi, et al.
Publicado: (2023)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
por: Kim, Kidae, et al.
Publicado: (2019)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
por: Chen, Jin‐Jiao, et al.
Publicado: (2023)

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

Computer aided drug design in the development of proteolysis targeting chimeras
por: Tunjic, Tin M., et al.
Publicado: (2023)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
por: Hu, Mingxing, et al.
Publicado: (2020)

Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
por: Ma, Ke, et al.
Publicado: (2021)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
por: Li, Xin, et al.
Publicado: (2022)

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
por: Zhao, Chunlong, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase
por: Sohbati, Hamidreza, et al.
Publicado: (2022)

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
por: Tseng, Yu-Ling, et al.
Publicado: (2023)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
por: Manda, Sudhakar, et al.
Publicado: (2020)

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
por: Zeng, Shenxin, et al.
Publicado: (2021)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras
por: Wen, Tianzhi, et al.
Publicado: (2023)

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2
por: Pan, Pengming, et al.
Publicado: (2023)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
por: Tashima, Toshihiko
Publicado: (2023)

PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020)

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
por: Wang, Yingying, et al.
Publicado: (2016)

A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019)

Oxidation resistance 1 is a novel senolytic target
por: Zhang, Xin, et al.
Publicado: (2018)

Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
por: Do, Thang Cong, et al.
Publicado: (2022)

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
por: Salami, Jemilat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h6mcbi8t5au5prtmsiu03t158c